Rhabdomyolysis Caused by Gefitinib Overdose

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are common therapeutic agents for EGFR mutation-positive advanced non-small-cell lung cancer. There has been no report of rhabdomyolysis caused by an overdose of EGFR-TKIs. We herein review the existing literature on the subje...

Full description

Saved in:
Bibliographic Details
Published inInternal Medicine Vol. 61; no. 10; pp. 1577 - 1580
Main Authors Niimi, Kyoko, Obayashi, Shohei, Oguma, Tsuyoshi, Tanaka, Jun, Ito, Yoko, Tomomatsu, Katsuyoshi, Hayama, Naoki, Urata, Mika, Asano, Koichiro
Format Journal Article
LanguageEnglish
Published Japan The Japanese Society of Internal Medicine 15.05.2022
Japan Science and Technology Agency
Subjects
Case Report
EGFR-TKI
Epidermal growth factor
Epidermal growth factor receptors
Gefitinib
Internal medicine
Non-small cell lung carcinoma
Overdose
Protein-tyrosine kinase
Rhabdomyolysis
overdose
rhabdomyolysis
EGFR-TKI
Online AccessGet full text
ISSN0918-2918
1349-7235
1349-7235
DOI10.2169/internalmedicine.8168-21

Cover

More Information
Summary:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are common therapeutic agents for EGFR mutation-positive advanced non-small-cell lung cancer. There has been no report of rhabdomyolysis caused by an overdose of EGFR-TKIs. We herein review the existing literature on the subject and report a rare case of rhabdomyolysis due to an overdose of gefitinib, an EGFR-TKI.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Report-1
ObjectType-Feature-4
content type line 23
ObjectType-Article-3
Correspondence to Dr.　Yoko Ito, itoy@tokai.ac.jp
ISSN:0918-2918
1349-7235
1349-7235
DOI:10.2169/internalmedicine.8168-21